🎯 Drug Targets

Browse 7 drug targets with druggability analysis, composite scores, and clinical context

7
Targets
0
High Druggability
0.56
Avg Score
15
Target Classes
Druggability Distribution
High: 0Medium: 0Low: 7Unknown: 0
Avg druggability score: 0.381
Clinical Pipeline
Approved: 1Phase III: 1Phase II: 2Phase I: 3Preclinical: 0
Total compounds: 7 · Approved: 1
Filtered by: class=ion_channel, druggability=Low — 7 results
AQP1 Aquaporin-1 Phase 4
Ion Channel Low Druggability
Score
0.62
Drug.
0.39
Safety
0.50
Drugs
1
Hyps
1
Papers
26
AQP1 functions as a water channel protein facilitating transmembrane water flux, with emerging evidence suggesting its involvement in neuroinflammatory processes and potential contribution to neuronal cell volume regulation and edema formation in neurodegenerative conditions. In the context of neurodegeneration, AQP1 may modulate neuronal and glial cell responses to oxidative stress, inflammation, and cellular metabolic perturbations, making it a potential strategic target for therapeutic intervention.
GJA1 Gap junction alpha-1 protein (Connexin 43) Phase 2
Ion Channel Low Druggability
Score
0.62
Drug.
0.36
Safety
0.50
Drugs
1
Hyps
3
Papers
54
Small molecule modulator of gap junction channel activity
MCOLN1 Mucolipin-1 Phase 1
Ion Channel Low Druggability
Score
0.59
Drug.
0.41
Safety
0.30
Drugs
1
Hyps
1
Papers
28
Small molecule agonists or modulators of lysosomal calcium channel activity
PIEZO1 Piezo-type mechanosensitive ion channel component Phase 1
Ion Channel Low Druggability
Score
0.55
Drug.
0.42
Safety
0.40
Drugs
1
Hyps
4
Papers
61
Small molecule modulator of mechanosensitive ion channel activity
CHR2 Channelrhodopsin-2 Phase 2
Ion Channel Low Druggability
Score
0.55
Drug.
0.33
Safety
0.80
Drugs
1
Hyps
1
Papers
18
CHR2 functions as a light-gated cation channel that opens in response to blue light (470nm), allowing depolarization through Na+ and Ca2+ influx. Therapeutic approaches would involve delivering CHR2 via gene therapy to degenerated neurons or photoreceptors, enabling light-dependent control of neural activity for vision restoration or neuromodulation applications.
MCU Mitochondrial calcium uniporter Phase 3
Ion Channel Low Druggability
Score
0.51
Drug.
0.41
Safety
0.25
Drugs
1
Hyps
3
Papers
31
MCU inhibitors block the mitochondrial calcium uniporter channel, reducing excessive calcium accumulation in mitochondria that leads to oxidative stress, energy depletion, and cell death. This mechanism may protect against ischemic injury, neurodegeneration, and heart failure by preserving mitochondrial function and preventing apoptosis in calcium-sensitive tissues.
AQP4 Aquaporin-4 Phase 1
Ion Channel Low Druggability
Score
0.46
Drug.
0.35
Safety
0.45
Drugs
1
Hyps
13
Papers
61
Water channel inhibitor or modulator